<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617004</url>
  </required_header>
  <id_info>
    <org_study_id>AOM12629_3</org_study_id>
    <nct_id>NCT02617004</nct_id>
  </id_info>
  <brief_title>Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults</brief_title>
  <acronym>GRAALL-2014/B</acronym>
  <official_title>Multicenter Trial Treatment of Philadelphia Chromosome Negative (Ph-) B-lineage Acute Lymphoblastic Leukemia (ALL) of Young Adults (18-59 Years).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively validate the new risk model, based on minimal
      residual disease (MRD) response level and oncogenetic status by comparing historical results
      of GRAALL-2005 with those of GRAALL-2014 in an identical population of patients (Philadelphia
      chromosome negative, B lineage ALL, aged 18 to 59 years old).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non relapse mortality (NMR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality (NRM) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      leukemic cells, nucleic acids, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Young Adults (age 18-59) with Philadelphia Chromosome Negative B-cell Acute Lymphoblastic
        Leukemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Whose blood and bone marrow explorations have been completed before the steroids
             prephase

          2. Aged 18 to 59 years old with not previously treated (including intrathecal injection)
             B-lineage-ALL newly diagnosed according to the WHO 2008 definition with ≥ 20% bone
             marrow blasts

          3. Whose karyotype shows no t(9;22) and/or the absence in molecular biology of breakpoint
             cluster region-Abelson (BCR-ABL)

          4. With Eastern Cooperative Oncology Group (ECOG) performance status ≤3

          5. With or without central nervous system (CNS) or testis involvement

          6. Without other evolving cancer (except basal cell carcinoma of the skin or &quot;in situ&quot;
             carcinoma of the cervix) or its radiotherapy or chemotherapy treatment should be
             finished at least since 6 months

          7. Having signed a written informed consent

          8. With efficient contraception for women of childbearing age (excluding estrogens and
             IUD)

          9. With health insurance coverage

         10. Who have received or being receiving the steroid prephase

        Exclusion Criteria:

          1. With lymphoblastic lymphoma and bone marrow blasts &lt; 20%, Burkitt-type ALL, or with
             antecedents of chronic myeloid leukemia (CML) or other myeloproliferative neoplasm

          2. With contra-indication to anthracyclines or any other general or visceral
             contra-indication to intensive therapy except if considered related to the ALL:

               -  Aspartate transaminase (AST) and/or alanine transaminase (ALT) &gt; 5 x upper limit
                  of normal range (ULN)

               -  Total bilirubin ≥ 2.5 x upper limit of normal range (ULN)

               -  Creatinine &gt;1.5x upper limit of normal range (ULN) or creatinine clearance &lt;50
                  mL/mn

          3. Myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy
             (NYHA grade III or IV), left ventricle ejection fraction (LVEF) &lt; 50% and or
             Shortening fraction &lt; 30%,

          4. Active severe infection or known seropositivity for HIV or human T cell
             leukemia/lymphoma virus type 1 (HTLV1) or active hepatitis B or C

          5. Pregnant (beta-Human Chorionic Gonadotropin positive) or nursing woman

          6. Not able to bear with the procedures or the frequency of visits planned in the trial

          7. Unable to consent, under tutelage or curators, or judiciary safeguard.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Dombret, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hervé Dombret, MDPhD</last_name>
    <phone>+33 (0)1 57 27 68 47</phone>
    <email>herve.dombret@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Lhéritier</last_name>
    <phone>+33(0)4 78 86 22 39</phone>
    <email>veronique.lheritier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hématologie Adulte, Saint Louis hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Dombret</last_name>
      <phone>+33 (0)1 57 27 68 47</phone>
      <email>herve.dombret@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

